International journal of cancer research and molecular mechanisms最新文献

Pilot Study to Determine the Prevalence of CYP2B6*6(C.516G>T), CYP2C19*2 (C.681G>A) and CYP2C19*3 (C.636G>A) in Breast Cancer Patients versus Normal Healthy Controls among Three Major Ethnic Groups in Singapore 测定新加坡三个主要民族乳腺癌患者与正常健康对照中CYP2B6*6(C.516G>T)、CYP2C19*2 (C.681G>A)和CYP2C19*3 (C.636G>A)患病率的初步研究

International journal of cancer research and molecular mechanisms Pub Date : 2022-01-01 DOI: 10.16966/2381-3318.154

S. Gh, Koo Sh, Tanrykuliev Pt, Lee Ls, Tham Ck, H. M, Tan Sm

引用次数: 0

Factors Affecting Colorectal Cancer Screening Among African-Born Immigrants in the United States: A Cross-Sectional Study 影响美国非洲裔移民结直肠癌筛查的因素:一项横断面研究

International journal of cancer research and molecular mechanisms Pub Date : 2022-01-01 DOI: 10.16966/2381-3318.152

Chibundu C, Beatty F, Akwafuo S

引用次数: 1

Is There Any Rationale for Detecting Hormone Receptor/HER2 Status with Rebiopsy Without Progression Upfront Metastatic Breast Cancer? with 2 Cases 没有进展的前期转移性乳腺癌再活检检测激素受体/HER2状态是否有任何理由?2箱

International journal of cancer research and molecular mechanisms Pub Date : 2021-01-01 DOI: 10.16966/2381-3318.148

Duman Bb, Cil T

{"title":"Is There Any Rationale for Detecting Hormone Receptor/HER2 Status with Rebiopsy Without Progression Upfront Metastatic Breast Cancer? with 2 Cases","authors":"Duman Bb, Cil T","doi":"10.16966/2381-3318.148","DOIUrl":"https://doi.org/10.16966/2381-3318.148","url":null,"abstract":"Alteration of biomarkers is well-documented in breast cancer at locoregional recurrence or metastasis attributed to tumor heterogeneity and change in biology. There is some data about discordance between primary and metastatic sites. At the same time hormone, receptor status can change after neoadjuvant treatment and at the time of recurrence. Metastatic breast cancer without progression or recurrence after the targeted chemotherapy combination for planning maintenance therapy in Human epidermal growth factor receptor 2 (HER2) overexpression positive hormone receptors positive or triple-negative patient after chemotherapy. In guidelines, the time of rebiopsy has no exact time, if the time of biopsy is usually after the progression of the tumor. We presented cases in which we detected different hormone receptor statuses from the beginning without progression and before deciding on maintenance therapy. This subject is important for deciding therapy in the aspect of heterogeneous tumors like breast cancer. The important decision of rebiopsy time is debate. In this aspect, these two cases are important examples for these kinds of patients tumor heterogeneity in breast cancer is one of the most widely known entities. We found that two patients, one of whom was estrogen progesterone receptor negative HER2 3 (+++) at the time of diagnosis and the other who was triple negative at the time of diagnosis, had positive hormone receptors in the re-biopsies without progression. We aimed to discuss the tumor heterogeneity and timing of rebiopsy in breast cancer in the light of two cases.","PeriodicalId":91280,"journal":{"name":"International journal of cancer research and molecular mechanisms","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67392937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could a Growth Inhibitory Factor, Present Only during Pregnancy, be Made Available to Treat Cancer in Adults? A Commentary 一种仅在怀孕期间存在的生长抑制因子能否用于治疗成人癌症?一篇评论

International journal of cancer research and molecular mechanisms Pub Date : 2021-01-01 DOI: 10.16966/2381-3318.149

Mizejewski Gj

引用次数: 0

Disintegrin-Like Peptides Derived from Naturally-Occurring Proteins: A Proposed Adjunct Treatment for Cancer Therapy: A Commentary 来自天然蛋白质的崩解素样肽:一种建议的辅助治疗癌症:评论

International journal of cancer research and molecular mechanisms Pub Date : 2021-01-01 DOI: 10.16966/2381-3318.147

Mizejewski Gj

{"title":"Disintegrin-Like Peptides Derived from Naturally-Occurring Proteins: A Proposed Adjunct Treatment for Cancer Therapy: A Commentary","authors":"Mizejewski Gj","doi":"10.16966/2381-3318.147","DOIUrl":"https://doi.org/10.16966/2381-3318.147","url":null,"abstract":"Disintegrins constitute a group of small proteins or peptides (45-85 amino acids) that function as natural antagonists of integrin receptor-dependent cell activities. The integrins themselves comprise a superfamily of hetero-dimeric (alpha and beta chains) transmembrane cell surface receptors whose functions include cell adhesion, growth, migration, and angiogenesis. In contrast, the disintegrins comprise groups of two types of molecules, namely, a) short proteins or peptides comprising insect and animal venoms; and b) intrinsic sub domain sequence fragments or short motifs present on large mammalian metalloprotease enzymes. Certain disintegrins bind specifically to tri-amino acid sequences (RGD, LGD etc) located on integrins beta-1 and beta-3 chains of the hetero complex receptors. Binding at such sites can inhibit or block cell migration, angiogenesis, metastasis, and platelet aggregation. Recently, small disintegrin-like peptides from naturally-occurring proteins have likewise been reported to inhibit growth and adhesion functions associated with integrin-dependent cell activities. The present report describes examples of such disintegrin-like peptides and provides support for their proposed use in adjunct cancer therapy.","PeriodicalId":91280,"journal":{"name":"International journal of cancer research and molecular mechanisms","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67392864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Assessment of Knowledge, Attitude and Practice of Breast Self-Examination among Reproductive Age Females in Altekaina Village, Sudan July 2018 2018年7月苏丹Altekaina村育龄妇女乳房自检知识、态度和行为评估

International journal of cancer research and molecular mechanisms Pub Date : 2020-01-01 DOI: 10.4172/1948-5956-C12-156

A. Wb, A. Nm, Bashir Ba

引用次数: 0

Androgen Receptor as a Potential Target for Treatment of Breast Cancer. 雄激素受体作为治疗乳腺癌的潜在靶点。

International journal of cancer research and molecular mechanisms Pub Date : 2017-04-01 Epub Date: 2016-10-06 DOI: 10.16966/2381-3318.129

Y Wu, J V Vadgama

{"title":"Androgen Receptor as a Potential Target for Treatment of Breast Cancer.","authors":"Y Wu, J V Vadgama","doi":"10.16966/2381-3318.129","DOIUrl":"https://doi.org/10.16966/2381-3318.129","url":null,"abstract":"Clinical studies have shown that the androgen receptor (AR) is ubiquitously expressed in breast cancers and this could provide prognostic implication in the diagnosis and treatment of breast cancers. Data from Nurse's Health Study on women with invasive breast cancer suggest that a significant number of tumors were AR-positive as defined by immunohistochemistry. In addition, the distribution of AR among different breast cancer subtypes varies significantly, and the biological reasons for this variation are not well understood. Despite strong histochemical evidence, the AR status is not applied for assessing pathological findings and disease outcome in clinical practice. AR antagonists are not currently used as therapy in breast cancer. This is in part due to conflicting results from early clinical trials with first generation of AR antagonists together with the complexity in breast cancer heterogeneity. In addition, role of AR in breast cancer is not fully understood. Here we will review the role of AR in different subtypes of breast cancers and elucidate its mechanisms. We will also discuss some recent interesting findings on the second generation of AR antagonists for treatment of breast cancer.","PeriodicalId":91280,"journal":{"name":"International journal of cancer research and molecular mechanisms","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34970347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Hematopoietic Stem Cell-derived Adipocytes Promote Tumor Growth and Cancer Cell Migration. 造血干细胞来源的脂肪细胞促进肿瘤生长和癌细胞迁移。

International journal of cancer research and molecular mechanisms Pub Date : 2017-01-01 Epub Date: 2017-03-08 DOI: 10.16966/2381-3318.130

Y Xiong, D L Russell, L T McDonald, L A Cowart, A C LaRue

{"title":"Hematopoietic Stem Cell-derived Adipocytes Promote Tumor Growth and Cancer Cell Migration.","authors":"Y Xiong, D L Russell, L T McDonald, L A Cowart, A C LaRue","doi":"10.16966/2381-3318.130","DOIUrl":"https://doi.org/10.16966/2381-3318.130","url":null,"abstract":"Adipocytes, apart from their critical role as the energy storage depots, contribute to the composition of the tumor microenvironment. Our previous studies based on a single hematopoietic stem cell (HSC) transplantation model, have revealed a novel source of adipocytes from HSCs via monocyte/macrophage progenitors. Herein, we extend these studies to examine the role of HSC-derived adipocytes (HSC-Ad) in tumor progression. When cultured under adipogenic conditions, bone marrow-derived monocytic progenitors differentiated into adipocytes that accumulated oil droplets containing triglyceride. The adipokine array and ELISAs confirmed secretion of multiple adipokines by HSC-Ad. These adipocytes underwent further development in vivo when injected subcutaneously into C57Bl/6 mice. When co-injected with melanoma B16F1 cells or breast cancer E0771 cells into syngeneic C57Bl/6 mice, HSC-Ad not only accelerated both melanoma and breast tumor growth, but also enhanced vascularization in both tumors. Conditioned media from HSC-Ad supported B16F1 and E0771 cell proliferation and enhanced cell migration in vitro. Among the HSC-Ad secreted adipokines, insulin-like growth factor 1 (IGF-1) played an important role in E0771 cell proliferation. Hepatocyte growth factor (HGF) was indispensable for B16F1 cell migration, whereas HGF and platelet-derived growth factor BB (PDGF-BB) collectively contributed to E0771 cell migration. Expression levels of receptors for IGF-1, HGF, and PDGF-BB correlated with their differential roles in B16F1 and E0771 cell proliferation and migration. Our data suggest that HSC-Ad differentially regulate tumor behavior through distinct mechanisms.","PeriodicalId":91280,"journal":{"name":"International journal of cancer research and molecular mechanisms","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35479083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia 低剂量顺铂治疗急性早幼粒细胞白血病的临床前评估

International journal of cancer research and molecular mechanisms Pub Date : 2015-10-01 DOI: 10.16966/2381-3318.113

Shaloam Dasari, Venkatramreddy Velma, C. Yedjou, P. Tchounwou

{"title":"Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia","authors":"Shaloam Dasari, Venkatramreddy Velma, C. Yedjou, P. Tchounwou","doi":"10.16966/2381-3318.113","DOIUrl":"https://doi.org/10.16966/2381-3318.113","url":null,"abstract":"Cis-diamminedichloroplatinum (II) (cisplatin) is the most widely used chemotherapeutic drug for various cancers, but its effectiveness is limited by tumor cell resistance and the severe side effects it causes. Since high level of cisplatin is cytotoxic to both cancer and normal cells, the goal of the present study was to explore the effectiveness of prolonged low doses of cisplatin in the management of leukemia. To achieve our goal, human leukemia (HL-60) cells were treated with different doses (1, 2, or 3 µM) of cisplatin for 24, 48, 72 and 96 hours. Cell viability was assessed by MTS assay. Both oxidative stress damage and genotoxicity were estimated by antioxidants, lipid peroxidation, and comet assays, respectively. Data obtained from the MTS assay demonstrated that cisplatin treatment decreased the number of viable tumor cells by direct cell killing or by simply decreasing the rate of cellular proliferation in a dose- and time-dependent fashion. The results of the lipid peroxidation showed a significant increase (p<0.05) of malondialdehyde levels with increasing cisplatin doses. Results obtained from super oxide dismutase and catalase assays showed a gradual increase in antioxidant enzyme activity in cisplatin-treated cells compared to control cells. Data generated from the Comet assay demonstrated a significant dose-dependent increase in genotoxicity with respect to DNA damage as a result of cisplatin treatment. Taken together, our research demonstrated that cisplatin-induced cytotoxicity in HL-60 cells is mediated at least in part via induction of oxidative stress and oxidative damage.","PeriodicalId":91280,"journal":{"name":"International journal of cancer research and molecular mechanisms","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67392843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort. 血液和体液中的可溶性 gC1qR：胰腺癌患者队列研究

International journal of cancer research and molecular mechanisms Pub Date : 2015-10-01 Epub Date: 2015-09-03 DOI: 10.16966/ijcrmm.110

Ellinor Ib Peerschke, Ricardo Jmge Brandwijk, Francine R Dembitzer, Yayoi Kinoshita, Berhane Ghebrehiwet

{"title":"Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort.","authors":"Ellinor Ib Peerschke, Ricardo Jmge Brandwijk, Francine R Dembitzer, Yayoi Kinoshita, Berhane Ghebrehiwet","doi":"10.16966/ijcrmm.110","DOIUrl":"10.16966/ijcrmm.110","url":null,"abstract":"Background: gC1qR is a multifunctional cellular protein that has been linked to inflammation and cancer. gC1qR is highly upregulated in adenocarcinomas as compared to normal tissue counterparts, and soluble gC1qR (sgC1qR) has been detected in vitro in the pericellular milieu of proliferating malignant cells.Aim: The present study explored the tissue expression of gC1qR in pancreatic cancer by immunohistochemistry, and the presence of sgC1qR in vivo, by examining blood and malignant effusions from patients with metastatic pancreatic adenocarcinoma.Methods: Tissue expression of gC1qR by pancreatic adenocarcinoma was visualized by immunohistochemistry. SgC1qR was quantified in serum from healthy volunteers (n=20) and pancreatic cancer patients (n=34), as well as in malignant pleural (n=23) and peritoneal effusions (n=27), using a newly developed, sensitive immunocapture sandwich ELISA.Results: Overexpression of gC1qR was confirmed in pancreatic adenocarcinoma compared to nonmalignant pancreatic tissue. Moreover, increased serum levels of sgC1qR (0.29 ± 0.22 ng/ml) were noted in patients with metastatic pancreatic cancer compared to healthy controls (0.15 ± 0.10 ng/ml) (mean ± S.D.) (p=0.035). In 11 of 16 patients for whom sequential samples were available, serum sgC1qR levels rose with disease progression, and paralleled changes in tumor biomarkers, CEA and CA19.9. In addition to blood, sgC1qR was detected in malignant pleural (0.55 ± 0.47 ng/ml) and peritoneal effusions (0.57 ± 0.38 ng/ml).Conclusion: This study provides the first evidence for the presence of sgC1qR in vivo. The ability to detect sgC1qR in blood and body fluids will enable further studies to elucidate its pathophysiology in malignancy.","PeriodicalId":91280,"journal":{"name":"International journal of cancer research and molecular mechanisms","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67395181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0